Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
- PMID: 25092143
- PMCID: PMC4262600
- DOI: 10.1038/leu.2014.235
Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.Blood. 2016 Aug 18;128(7):971-81. doi: 10.1182/blood-2015-11-684225. Epub 2016 Jun 22. Blood. 2016. PMID: 27335278 Free PMC article.
-
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29. Blood. 2013. PMID: 23361907 Free PMC article.
-
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5. J Hematol Oncol. 2012. PMID: 22397365 Free PMC article.
-
IDH mutations in acute myeloid leukemia.Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Hum Pathol. 2012. PMID: 22917530 Review.
-
Overview: A New Era of Cancer Genome in Myeloid Malignancies.Oncology. 2015;89 Suppl 1:1-3. doi: 10.1159/000431054. Epub 2015 Nov 10. Oncology. 2015. PMID: 26551625 Review.
Cited by
-
Functional interdependence of BRD4 and DOT1L in MLL leukemia.Nat Struct Mol Biol. 2016 Jul;23(7):673-81. doi: 10.1038/nsmb.3249. Epub 2016 Jun 13. Nat Struct Mol Biol. 2016. PMID: 27294782
-
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.Blood Adv. 2024 Apr 23;8(8):2005-2017. doi: 10.1182/bloodadvances.2023010805. Blood Adv. 2024. PMID: 38306602 Free PMC article.
-
Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.Front Oncol. 2017 Oct 12;7:241. doi: 10.3389/fonc.2017.00241. eCollection 2017. Front Oncol. 2017. PMID: 29075615 Free PMC article. Review.
-
Targeted Therapies for Pediatric AML: Gaps and Perspective.Front Pediatr. 2019 Nov 15;7:463. doi: 10.3389/fped.2019.00463. eCollection 2019. Front Pediatr. 2019. PMID: 31803695 Free PMC article. Review.
-
Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Adv Drug Deliv Rev. 2017 May 15;114:285-300. doi: 10.1016/j.addr.2017.06.010. Epub 2017 Jun 15. Adv Drug Deliv Rev. 2017. PMID: 28625826 Free PMC article. Review.
References
-
- Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous